The American Academy of Pediatrics has updated its policy to fully endorse generic drugs and biosimilars for children and adolescents, citing their safety, effectiveness, and cost savings. - The policy, published May 26, 2026, in Pediatrics, recognizes that 91% of U.S.
prescriptions are generic. - It recommends pediatricians trust substitutions for generic drugs and interchangeable biologics.
- The AAP calls for more research, harmonized state laws, and transparent pricing to improve access. This update aims to reassure families that generics are a reliable and affordable treatment option.